{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-024339","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.589530+00:00","generated_at":"2026-05-15T18:58:26.942428+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes","bullets":["Issued $10.93M A-1 Note (9% interest) and $10M secured B Note (5% interest) for $20M purchase price.","$900K OID and $30K expense included; maturity 18 months from March 2, 2026.","B Note secured by $10M deposit account and pledge of ALLR Holdings LLC; guaranteed by three subsidiaries.","Covenants restrict additional debt, variable-rate issuances, and asset encumbrances without lender consent.","Investor can redeem up to $250K/month starting 6 months after closing; trigger events allow 10%/5% balance increases."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-024339","json":"https://secwatch.observer/filing/0001213900-26-024339.json","markdown":"https://secwatch.observer/filing/0001213900-26-024339.md","text":"https://secwatch.observer/filing/0001213900-26-024339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/ea0279478-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:58:26.942428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40d6764414716792a8fd029130a8d142a6fcff72","claim":"Allarity Therapeutics, Inc. incurred loan of $10,930,000 (A-1 Note) and $10,000,000 (B Note) with Streeterville Capital, LLC at 9.00% per annum and 5.00% per annum maturing 18 months following the date of issuance.","evidence_excerpt":"On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$10,930,000 (A-1 Note) and $10,000,000 (B Note)"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Rate","value":"9.00% per annum and 5.00% per annum"},{"label":"Maturity","value":"18 months following the date of issuance"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"2ed43a922b72a2042543758eb2fafac44058eb15","claim":"Allarity Therapeutics, Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000) (effective 2026-03-02).","evidence_excerpt":"On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000)"},{"label":"Effective","value":"2026-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}